![]() |
|
|
Vol. 55, Issue 5, 804-811, May 1999
Howard Hughes Medical Institute, Department of Biochemistry, New York University Medical Center, New York, New York (F.S.V., B.S., E.Z.); Department of Anatomy (A.A.A.) and Department of Pharmacology and Toxicology (V.K.K., E.K.), Institute of Biomedicine, University of Helsinki, Helsinki, Finland; and Department of Biology, Abo Akademi University, Biocity, Turku, Finland (M-L.N., M.L., K.K., P.P.)
| |
Summary |
|---|
|
|
|---|
Neuropeptides FF (NPFF), AF (NPAF), and SF (NPSF) are homologous amidated peptides that were originally identified on the basis of similarity to the molluscan neuropeptide FMRF-amide. They have been hypothesized to have wide-ranging functions in the mammalian central nervous system, including pain modulation, opiate function, cardiovascular regulation, and neuroendocrine function. We have cloned the NPFF gene from human, bovine, rat, and mouse, and show that the precursor mRNA encodes for all three of the biochemically identified peptides (NPFF, NPAF, and NPSF). We demonstrate that NPFF precursor mRNA expression by Northern analysis and map sites of expression by in situ hybridization. We confirm the validity of the in situ hybridization by showing that its distribution in the brain and spinal cord matches the distribution of NPFF and NPSF immunoreactivity. We go on to show that the mRNA levels (as measured by in situ hybridization) in the spinal cord can be up-regulated by a model for inflammatory pain (carrageenan injection), but not by a model for neuropathic pain (lumbar nerve ligation). Our results confirm the evolutionary conservation of NPFF, NPAF, and NPSF neuropeptide expression in mammalian brain. They also provide a context for the interpretation of the pain-sensitizing effects of injections of these peptides that have been previously reported. Our results support a model for the role of these peptides in pain regulation at the level of the spinal cord.
| |
Introduction |
|---|
|
|
|---|
Neuropeptides
FF (NPFF), AF (NPAF), and SF (NPSF) (Yang et al., 1985
; Yang and
Martin, 1995
) are related mammalian neuropeptides that were originally
identified by their similarity to the molluscan cardioactive peptide
FMRF-amide (Price and Greenberg, 1977
). These mammalian neuropeptides
have been implicated in pain modulation (Yang et al., 1985
; Gouarderes
et al., 1993
), opiate function (Tang et al., 1984
; Malin et al., 1990
),
cardiovasvcular regulation (reviewed by Panula et al., 1996
), and
neuroendocrine function (Majane and Yang, 1990
; Majane et al., 1993
).
The peptides may be involved in hypothalamic regulation of pituitary
functions because they are present in the hypothalamo-pituitary system, they decrease during salt-loading, and are deficient in the pituitary gland of vasopressin-deficient rats (Majane and Yang, 1990
; Majane et
al., 1993
). Peripherally administered NPFF raises blood pressure in
rats, an effect mediated by both peripheral and central mechanisms (reviewed by Panula et al., 1996
).
NPFF has been implicated in sensory systems, most notably pain and
morphine analgesia (Yang et al., 1985
). Intracerebroventricular NPFF
has been reported to induce a vigorous abstinence syndrome in
morphine-tolerant rats (Malin et al., 1990
). NPFF also has been shown
to regulate the density of opioid receptors (Rothman et al., 1991
;
Goodman et al., 1996
) and modulate self-administration of morphine
(Goodman, 1995
). When administered in the third ventricle, NPFF can
attenuate the antinociceptive effects of morphine (Tang et al., 1984
),
but intrathecal NPFF can produce long-lasting antinociception (Gouarderes et al., 1993
). These seemingly contradictory results may
reflect multiple roles for NPFF in modulation of pain pathways, including modulation of ascending systems, the three-tiered descending pain control system and local circuits in the dorsal horn. Involvement in sensory pain systems, autonomic regulation, and hypothalamic functions is in agreement with the known limited distribution of NPFF
immunoreactive neurons in the medullary, hypothalamic, and spinal
locations (reviewed by Panula et al., 1996
). A specific binding site
for NPFF in the central nervous system (CNS) has been described (Allard
et al., 1989
), which may correspond to a G protein-coupled receptor
that mediates NPFF's effects on opioid pharmacology and receptor
binding. NPFF may potentiate the effects of morphine and endogenous
opioids on primary afferents in the dorsal horn, but exert antiopioid
actions on the control of supraspinal descending neurons through
interneurons. Indeed, enkephalins modulate not only the ascending
sensory pain mechanisms but also all three levels of the descending
system, specifically the periaqueductal gray, rostral ventral medulla
and dorsal horn of the spinal cord (Basbaum and Fields, 1984
).
NPFF-immunoreactive nerve terminals and binding sites are also found on
all these levels (reviewed by Panula et al., 1996
).
To study the function of this neuropeptide further, we sought to clone
the precursor mRNA and to examine possible regulation of the gene.
Perry et al. (1997)
identified an mRNA coding for the NPFF precursor
from human testis cDNA, but did not describe the distribution of the
mRNA in brain. Here we report the cloning of the NPFF precursor
mRNAs from human hypothalamus in addition to bovine, rat, and mouse
brainstem and hypothalamus cDNA. We show that the NPFF gene in human,
murine, bovine, and rat tissues is highly conserved and encodes
polypeptides 113 to 115 amino acids long, which are the precursor to
NPFF, NPAF, and NPSF. We analyze the expression of NPFF mRNA in the
brain and spinal cord and show that its distribution matches that of
the NPFF and NPSF peptide immunoreactivity, thus validating the results
of the in situ analysis. We provide evidence that the NPFF gene is
specifically induced in the dorsal horn by inflammatory pain. We
present a model in which activity-dependent control of the NPFF gene
contributes to the regulation of pain perception.
| |
Materials and Methods |
|---|
|
|
|---|
Cloning.
Human and rat genomic libraries were obtained from
Stratagene (La Jolla, CA). A Y129 mouse genomic library was a kind gift from Dr. Alex Joyner (New York University, School of Medicine, New
York). Bovine genomic DNA was extracted from bovine brain using
proteinase K digestion, phenol chloroform extraction, and ethanol
precipitation. Bovine, rat, and mouse brains were obtained frozen in
liquid nitrogen (Harlan Sprague-Dawley, Indianapolis IN) and processed
using acid-phenol to extract total RNA (Chomczynski and Sacchi, 1987
).
mRNA was isolated from total RNA using chromatography over oligo(dT)
cellulose (Fast Track; Invitrogen, Carlsbad, CA). First-strand cDNA was
synthesized from 1 µg of mRNA using avain myeloblastosis virus
reverse transcriptase (cDNA cycle kit; Invitrogen). Directional cDNA
libraries from bovine brainstem and rat hypothalamus and brainstem mRNA
were made with the Uni Zap kit (Stratagene) according to the
manufacturer's recommendations. Human rapid amplification of cDNA ends
(RACE)-ready hypothalamus cDNA (Marathon) was purchased from Clontech
(Palo Alto, CA). We also used single-stranded oligonucleotide ligation
onto first-strand bovine and rat cDNA to perform 5' RACE (Amplifinder;
Clontech). Rat and bovine NPFF mRNA 5' termini were mapped to genomic
sequences by sequencing clones of 5' RACE products, and the mouse 5'
terminus was mapped by sequencing clones of reverse transcription-polymerase chain reaction (PCR) products and by inference
from the rat structure. PCR was performed with Amplitaq DNA polymerase
on a GeneAmp DNA thermal cycler (Perkin-Elmer, Norwalk CT) using 1 µM
of primers and 200 µM of each dNTP. PCR products were subcloned into
the T/A cloning vector (Invitrogen) and sequenced using dye termination
(Perkin-Elmer, Applied Biosystems International, Foster City,
CA). In all cases, at least three PCR clones were analyzed to obtain
consensus sequences. Northern blots were performed on 20 µg of total
RNA run on 1.5% agarose formaldehyde/3-(N-morpholino)propanesulfonic acid gels and
proteins were transferred (Turboblotter; Schleicher & Schuell, Keene,
NH) using 20 times standard saline phosphate EDTA onto
positively charged nylon (Pall BioDyne B; Life Technologies,
Gaithersburg, MD). The RNA was UV cross-linked to the membrane
(Stratalinker; Stratagene) and probed using random primed (Boehringer
Mannheim, Indianapolis IN) [32P]dCTP (NEN,
Boston, MA)-labeled cDNA in QuickHyb (Stratagene).
In Situ Hybridization.
Male Wistar rats (250-300 g) were
decapitated, and tissues removed and frozen in dry ice-cooled
isopentane (Fluka Chemie AG, Buchs, Switzerland). Coronal sections
20-µm thick cut from tissues embedded in Tissue Tek (Miles, Inc.,
Elkhart, IN) were thaw mounted on poly-L-lysine (Sigma, St.
Louis MO)-coated glass slides and stored at
70°C until used. High
specific activity RNA probes were generated from the full-length
NPFF-cDNA cloned in PGEM-3Z using the Riboprobe Combination System kit
(Promega, Madison WI) in combination with T7 RNA polymerase (Promega)
and [35S]UTP (ICN, Costa Mease, CA). Sense and
antisense probes were prepared from XbaI (Promega)
linearized template. Frozen sections were fixed for 10 min in ice-cold
4% paraformaldehyde (J. T. Baker, Deventer, Holland) in PBS (pH
7.4), washed twice for 5 min in PBS at room temperature and once in 2×
standard saline citrate (SSC) (1× SSC: 0.3 M NaCl and 0.15 M sodium
citrate, pH 7.0), and illuminated with UV light for 5 min. After
ethanol dehydration and chloroform delipidation, the sections were
incubated at 50°C for 1 h with prehybridization solution (50%
formamide, 0.6 M NaCl, 2.5× Denhardt's solution, 1 mM EDTA, 500 µg/ml type III salmon sperm DNA, 500 µg/ml type III baker's yeast
total RNA (Sigma), 50 µg/ml baker's yeast transfer RNA (Boehringer
Mannheim, Germany), and 10 mM Tris-HCl, pH 7.5). The sections were then
hybridized at 50°C for 20 to 24 h with NPFF antisense or sense
cRNA probes (107 cpm/ml in 50% formamide, 0.6 M
NaCl, 2.5× Denhardt's solution, 1 mM EDTA, 10%
Na+ dextran sulfate (Pharmacia, Uppsala, Sweden),
10 mM dithiotreitol (DTT), 100 µg/ml type III salmon sperm DNA
(Sigma), 50 µg/ml type III baker's yeast total RNA (Sigma), 50 µg/ml transfer RNA, and 10 mM Tris-HCl, pH 7.5. After hybridization,
the slides were washed twice for 30 min in 2× SSC containing 0.3 mM
DTT at 56°C, RNase A (Boehringer Mannheim GmbH, Mannheim,
Germany)-treated for 30 min at 37°C (20 µg/ml in 0.5 M NaCl and
0.01 M Tris-HCl, pH 7.5), and washed again twice for 30 min in 2× SSC
containing 0.3 mM DTT. The final 30-min and 3-h high stringency washes
were performed in 0.1× SSC containing 0.3 mM DTT, 14 mM
-mercaptoethanol, and 0.005% sodium pyrophosphate at 56°C. The
slides were then allowed to cool to room temperature before dehydration
in ethanol (50%, 70%, and absolute ethanol containing 0.3 M ammonium
acetate). Slides were then apposed to Kodak BioMax MR film (Eastman
Kodak, New Haven, CT) for 2 weeks. Images were acquired with the Adobe Photoshop program and printed to produce pictures. Quantification of
autoradiographic films was carried out by digitizing the film images
with a computer-based image analysis system (the MCID Program, Imaging
Research Inc., Ontario, Canada) and by measuring the gray-scale pixel values from the laminae of the dorsal horn. Relative optic density values indicating expression of specific NPFF mRNA were obtained based on a 14C standard curve with
correction for background. Nonparametric ANOVA was applied. After film
exposure, sections were dipped in photographic emulsion NTB 2 (diluted
1:1 with distilled water; Eastman Kodak) and exposed for 56 days. After
development, representative sections were stained with toluidine blue,
and samples were embedded in Permount (Fisher Chemical, Fair Lawn, NJ).
NPFF mRNA-expressing neurons were counted from spinal cord L5-6
segments on both sides after carrageenan inflammation. Every third
section was included. Background densities were obtained from
representative areas outside the positive cell areas. These values were
1.5 to 3.2 grains/100 µm2. Neurons with grain
densities more than 10 times higher than background values were
considered positive. The results were analyzed using the paired
t test. Analysis of NPFF mRNA was carried out by
quantitative in situ hybridization because of the low level of
expression. This method allows analysis of individual rats without
pooling of the samples.
Immunohistochemistry. Immunohistochemistry was performed using specific antisera against the C-termini of the two active peptides, NPFF and NPSF, present in the NPFF precursor. The peptides FLFQPQRF-NH2 (NPFF) and SLAAPQRF-NH2 (NPSF) were synthesized by solid-phase chemistry, purified by reverse-phase chromatography, and single peaks were verified using mass spectrometry. Peptides (5 mg of each) were coupled to succinylated keyhole limpet hemocyanin (Sigma) with l-ethyl-3,3 (dimethylaminopropyl) carbodiimide (Sigma) and antisera were produced in rabbits. Multiple intradermal injections and complete Freund's adjuvant were used in primary immunization, followed by intradermal injection of the conjugate in incomplete Freund's adjuvant 5 weeks later. Sera were tested for reactivity on nitrocellulose filters and brain sections every 10 days after the second immunization. Normal or colchicine (Sigma)-treated male Wistar rats (250-300 g) were perfused with 4% paraformaldehyde and brain sections were processed for immunofluorescence as described previously. Primary antisera were diluted 1:500 to 1:10000, and preadsorption controls with several peptides were carried out as described earlier. Permissions for animal experiments were obtained from Departmental Committees for Animal Experiments.
Carrageenan Inflammation.
The rats were anesthetized with
halothane and carrageenan (Sigma); 0.2 mg in 0.1 ml saline was injected
into the palm of the left hindpaw 3 h before the rats were
sacrificed. The resulting inflammation was quantified by cutting both
hindpaws from the knee joint and weighing immediately after the rats
were sacrificed to verify the effect of carrageenan as reported earlier
(Kontinen et al., 1997
). No blood loss occurred during the procedure.
It has been shown that a typical hyperalgesia and allodynia develop in
these animals (Kontinen et al., 1997
).
Neuropathic Pain Model.
The model of Kim and Chung (1992)
was used. The animals were anesthetized with halothane, and the left
L5-6 spinal nerves were exposed, isolated, and ligated tightly with
6-0 silk thread. Rats that developed significant mechanical allodynia
(threshold for paw withdrawal after von Frey hair stimulation with the
force of 4.2 g or less) at 2 weeks from the ligation were used.
This time point was selected as most relevant because the allodynia was
fully developed. A change before this time point might reflect the
effect of acute nerve ligation rather than a well-developed neuropathic
state. Permissions for animal experiments were obtained from
Departmental Committees for Animal Experiments.
| |
Results |
|---|
|
|
|---|
Gene and mRNA for NPFF and Deduced Precursor.
We cloned the
gene and cDNA encoding the NPFF precursor to reveal the processing and
regulation of active NPFF and NPFF's role in sensory and autonomic
functions. The organization of the NPFF gene from human, murine,
bovine, and rat (Fig. 1) is conserved among the four species, with two introns in the gene, both of which
fall in coding regions. The sequences of the first 500 nucleotides of
the 5' flanking regions of the rat and mouse genes are conserved greater than 90% and a TATA box precedes the mRNA start point of both
genes. The mRNA 5' untranslated region is short, approximately 13 nucleotides long. Despite repeated cloning efforts, no alternatively spliced mRNAs were detected. The structure of the NPFF precursor peptide deduced from human hypothalamus cDNA is identical with the one
derived from human testis cDNA that was recently reported (Perry et
al., 1997
). The mRNAs from the four species range from 600 to 800 in
length and encode highly related precursor polypeptides, 113 to 115 amino acids long (Fig. 2). All contain
signal peptide sequences at their N termini and have predicted signal
peptide cleavages immediately before glutamate 22 (23 in bovine)
(Nielsen et al., 1997
). The precursors have overall sequence identities of 40%, with 88% identity between rat and mouse and 71% between bovine and human. Within the sequences of these precursors, we identified structures corresponding to three peptides previously isolated in vivo, NPFF, NPAF, and NPSF. Also present for these precursors are C-terminal consensus sequences for peptide processing (reviewed by Eipper et al., 1992
), whose cleavage would yield the
predicted mature amidated peptides. In addition, the predicted mature
peptides all share the C-terminal sequence, PQRF-amide, which has been
shown to be essential for peptide biological activity (Payza and Yang,
1993
). Cleavage at the predicted N-terminal processing sites, however,
does not yield termini that correspond as clearly to those reported for
the peptides isolated in vivo (Yang et al., 1985
). There is a conserved
processing site three amino acids N-terminal to the amino terminus of
the biochemically isolated NPFF. It is possible that other mechanisms
besides precursor cleavage are responsible for producing the mature
peptide or that the biochemically isolated peptides experienced some
degradation. Another potential peptide upstream of NPFF, ending in
RP-amide, could be processed from the bovine and human precursors, but
is not conserved in mouse or rat.
|
|
mRNA and Peptide Expression.
We used in situ hybridization to
characterize the areas and cell types that express NPFF mRNA in the
CNS. Expression of NPFF mRNA in normal rat brain was limited to
hypothalamus, medulla, and dorsal horn of the spinal cord. Neurons in
the paraventricular (Fig. 3) and
supraoptic nucleus displayed moderate levels of NPFF mRNA. No mRNA
expression was seen in the medial hypothalamus between the dorsomedial
and ventromedial nuclei in normal or colchicine-treated animals. A very
strong signal was seen in the nucleus of the solitary tract (Fig. 3),
especially in its lateral part. A strong signal was also seen in the
spinal nucleus of the trigeminal nerve (Fig. 3) and in the dorsal horn
of the spinal cord (Fig. 3) at all levels. The signal was limited to
the superficial laminae. No NPFF mRNA was found in the posterior
pituitary. In peripheral tissues, the adrenal medulla, testis, heart,
duodenum, and pancreas displayed no signal. NPFF mRNA was detected by
Northern blotting as a 600-nucleotide species in hypothalamus and
brainstem (Fig. 3).
|
|
Regulation by Inflammatory Pain.
To assay for regulation of
the NPFF gene by pain-inducing stimuli, we subjected rats to two pain
protocols. For one, a neuropathic pain model, L5-6 spinal nerves were
ligated. For the second, a noxious irritant model for inflammatory
pain, carrageenan, was injected into the left hind paw. The levels of
NPFF mRNA in the dorsal horn were determined by in situ hybridization
and quantitative autoradiography. Fully developed neuropathy was not
associated with changes in NPFF mRNA levels, whereas a significantly
elevated signal was seen in the ipsilateral dorsal horn on level L4-6
after paw inflammation (Fig. 5). In the
experiment displayed in Fig. 5, all sections (25/group) were exposed
for autoradiography simultaneously. In other, independent experiments
(data from a total of 11 rats), the expression of NPFF mRNA was also
significantly higher on the carrageenan side than on the control side
(p = .0037, data not shown), confirming this result. To
elucidate further the nature of the increase in NPFF mRNA in the spinal
cord in carrageenan-treated rats, NPFF mRNA expression was analyzed by
a second technique. We subjected spinal cord sections to in situ
hybridization and autoradiography to identify individual cells
expressing NPFF mRNA. We then counted the number of cells expressing
NPFF mRNA on the treated and control sides of the dorsal horn in each
rat. The number of NPFF mRNA-expressing cell profiles (Fig. 5, G and H) in the spinal cord sections was 16.4 ± 0.9 (mean ± S.E.M.)
in the inflammation side and 10.7 ± 0.7 in the contralateral side (n = 4, p = .0029 in paired
t test). Thus, there was an increase following carrageenan
treatment of approximately 60% in the number of cells on the treated
versus the control side that express NPFF mRNA. This indicates that the
increase in NPFF mRNA results from the induction of the mRNA in newly
expressing cells of the dorsal horn, or in cells in which the
expression level under normal conditions is below the detection limit
of the method. The inflammatory pain protocol therefore causes a
significant increase in the number of NPFF-expressing neurons, rather
than simply an elevation of NPFF expression in neurons that expressed
the NPFF gene before carrageenan treatment. The increase in the number
of NPFF mRNA containing cells in laminae I-II on the inflammation side
as compared with the control side is shown in a representative section
in Fig. 6. We conclude that the NPFF gene
is induced in intrinsic neurons of the superficial laminae of the
dorsal horn by noxious insults associated with carrageenan injection.
|
|
| |
Discussion |
|---|
|
|
|---|
Cloning of the NPFF gene and mRNA in four species demonstrates
that in the bovine, rat, mouse, and human CNS, a single gene encodes
the peptide precursor to three related peptides, NPFF, NPAF, and NPSF.
Sequencing indicates that the peptides are released from a common
precursor polypeptide by N- and C-terminal processing, each potentially
involving several known, and potentially some unknown, peptide
maturation steps. A similar conclusion for human was reached by cDNA
analysis (Perry et al., 1997
). We also show that the NPFF gene is
induced by inflammatory pain.
Expression of NPFF in Brainstem and Spinal Cord.
In situ
hybridization reveals that the nucleus of the solitary tract and dorsal
horn of the spinal cord express the highest levels of NPFF mRNA. NPFF
immunoreactivity is also found at these sites (Panula et al., 1996
).
The moderate expression in the hypothalamic supraoptic and
paraventricular nuclei shows that this precursor is expressed in the
hypothalamo-pituitary system and gives rise, at least in part, to the
NPFF-like peptides detected in this region. Because the number of NPFF-
and NPSF-immunoreactive neurons was low even after colchicine
treatment, the mature peptides may be rapidly transported to the distal
compartments of the neurons. The central hypothalamic cell group
between the dorsomedial and ventromedial nucleus apparently also
contains NPFF-like peptides (Panula et al., 1996
). This group of cells
projects to the septum, amygdala, and nucleus of the solitary tract,
thus connecting the hypothalamus with the limbic system and medullary
autonomic system. However, lack of NPFF precursor mRNA suggests that
these cells may express other closely related peptides.
NPFF Mechanisms in Dorsal Horn.
Intracerebroventricular
infusion of NPFF elicits hyperalgesia in normal rats (Yang et al.,
1985
; Oberling et al., 1993
). Hyperalgesia is also a characteristic
feature in inflammatory pain models (Hargreaves et al., 1988
). However,
a long-lasting analgesic effect (Gouarderes et al., 1993
) and
potentiation of the analgesic effect of morphine (Kontinen and Kalso,
1995
) have been found after intrathecal NPFF. Thus, NPFF is a
potentially important regulator of pain transmission.
Induction of NPFF Gene by Inflammatory Pain.
There is now
clear evidence that carrageenan-induced inflammation induces NPFF
expression in ipsilateral spinal cord. We have shown that expression of
NPFF mRNA increases significantly, as measured by whole-section
autoradiography and by counting NPFF mRNA-expressing cells. NPFF
peptide levels also increase in neuronal cell bodies of the ipsilateral
spinal cord (Kontinen et al., 1997
). In the current study, carrageenan
induced a statistically highly significant 1.4-fold increase in NPFF
mRNA per section side. Analysis at the cellular level revealed that
this increase resulted from a 60% increase in the number of NPFF mRNA
expressing cells. Thus, the NPFF promoter is subject to strong
activity-dependent regulation by the inflammation protocol in a
specific reactive cell population. The induction follows the pattern
previously demonstrated for dynorphin, preproenkephalin, and
preprotachykinin A expression (Iadarola et al., 1988
; Minami et al.,
1989
; Noguchi et al., 1989
; Noguchi and Ruda, 1992
). In the carrageenan
model of inflammatory pain, both hyperalgesia and increased opioid
sensitivity may result from the activation of different classes of
nociceptive nerves and an increase in several neuropeptides. Decrease
in synthesis of cholecystokinin, a neuropeptide with antiopioid
characteristics, following carrageenan inflammation (Dray et al., 1994
)
may also contribute to hyperalgesia and opioid sensitivity.
|
| |
Acknowledgments |
|---|
We thank A. Joyner for the Y129 mouse genomic library and T. Serra for assistance in preparation of the manuscript.
| |
Footnotes |
|---|
Received July 2, 1998; Accepted February 3, 1999
Supported by Medical Research Council of Finland, Juselius Foundation and Signal Transduction Program of Åbo Akademi University and Howard Hughes Medical Institute (HHMI). F.S.V. was an Associate and E.B.Z. is an Investigator of HHMI. Portions of this work were previously presented in abbreviated fashion in the following abstracts: Vilim FS and Ziff E (1995) Cloning of the neuropeptide NPFF and NPAF precursor from bovine, rat, mouse, and human. Neurosci Abstr 21:760; Panula P, Nieminen M, Aarnisalo AA, Lintunen M, Karhunen T, Vilim FS, Ziff E and Karlstedt K (1996) Expression of neuropeptide FF precursor in rat CNS. Soc Neurosci Abstr 22:1557; Aarnisalo AA, Nieminen M, Kontinen V, Vilim FS, Kalso E, Ziff E and Panula P (1997) Expression of NPFF mRNA in carrageenan inflammation in the spinal cord. Soc Neurosci Abstr 23:1806.
Send reprint requests to: Dr. Edward B. Ziff, Howard Hughes Medical Institute, New York University Medical Center, Department of Biochemistry, 550 First Ave., New York, NY. E-mail: edward.ziff{at}med.nyu.edu
| |
Abbreviations |
|---|
NPFF, neuropeptide FF; NPAF, neuropeptide AF; NPSF, neuropeptide SF; CNS, central nervous system; RACE, rapid amplification of cDNA ends; PCR, polymerase chain reaction; DTT, dithiotreitol; SP, Substance P; PAN, primary afferent nociceptor.
| |
References |
|---|
|
|
|---|
2-adrenergic and µ-opioid spinal antinociception by neuropeptide FF.
Peptides
16:
973-977[Medline].This article has been cited by other articles:
![]() |
F. G. Revel, M. Saboureau, P. Pevet, V. Simonneaux, and J. D. Mikkelsen RFamide-Related Peptide Gene Is a Melatonin-Driven Photoperiodic Gene Endocrinology, March 1, 2008; 149(3): 902 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Jhamandas, F. Simonin, J.-J. Bourguignon, and K. H. Harris Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2007; 292(5): R1872 - R1880. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A Bechtold and S. M Luckman The role of RFamide peptides in feeding J. Endocrinol., January 1, 2007; 192(1): 3 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. Che, Q. Yuan, E. Kalinina, and L. D. Fricker Peptidomics of Cpefat/fat Mouse Hypothalamus: EFFECT OF FOOD DEPRIVATION AND EXERCISE ON PEPTIDE LEVELS J. Biol. Chem., February 11, 2005; 280(6): 4451 - 4461. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schachtner, B. Trosowski, W. D'Hanis, S. Stubner, and U. Homberg Development and steroid regulation of RFamide immunoreactivity in antennal-lobe neurons of the sphinx moth Manduca sexta J. Exp. Biol., June 15, 2004; 207(14): 2389 - 2400. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chartrel, C. Dujardin, Y. Anouar, J. Leprince, A. Decker, S. Clerens, J.-C. Do-Rego, F. Vandesande, C. Llorens-Cortes, J. Costentin, et al. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity PNAS, December 9, 2003; 100(25): 15247 - 15252. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Engstrom, A. Brandt, S. Wurster, J.-M. Savola, and P. Panula Prolactin Releasing Peptide Has High Affinity and Efficacy at Neuropeptide FF2 Receptors J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 825 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mzhavia, H. Pan, F.-Y. Che, L. D. Fricker, and L. A. Devi Characterization of Endothelin-converting Enzyme-2. IMPLICATION FOR A ROLE IN THE NONCLASSICAL PROCESSING OF REGULATORY PEPTIDES J. Biol. Chem., April 18, 2003; 278(17): 14704 - 14711. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Han, X. Dong, J.-I. Hwang, M. J. Zylka, D. J. Anderson, and M. I. Simon Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway PNAS, November 12, 2002; 99(23): 14740 - 14745. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Lefrere, P. de Coppet, J.-C. Camelin, S. Le Lay, N. Mercier, N. Elshourbagy, A. Bril, I. Berrebi-Bertrand, B. Feve, and S. Krief Neuropeptide AF and FF Modulation of Adipocyte Metabolism. PRIMARY INSIGHTS FROM FUNCTIONAL GENOMICS AND EFFECTS ON beta -ADRENERGIC RESPONSIVENESS J. Biol. Chem., October 11, 2002; 277(42): 39169 - 39178. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. Che, L. Yan, H. Li, N. Mzhavia, L. A. Devi, and L. D. Fricker Identification of peptides from brain and pituitary of Cpefat/Cpefat mice PNAS, July 24, 2001; (2001) 161542198. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Bonini, K. A. Jones, N. Adham, C. Forray, R. Artymyshyn, M. M. Durkin, K. E. Smith, J. A. Tamm, L. W. Boteju, P. P. Lakhlani, et al. Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF J. Biol. Chem., December 8, 2000; 275(50): 39324 - 39331. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Elshourbagy, R. S. Ames, L. R. Fitzgerald, J. J. Foley, J. K. Chambers, P. G. Szekeres, N. A. Evans, D. B. Schmidt, P. T. Buckley, G. M. Dytko, et al. Receptor for the Pain Modulatory Neuropeptides FF and AF Is an Orphan G Protein-coupled Receptor J. Biol. Chem., August 18, 2000; 275(34): 25965 - 25971. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Liu, X.-M. Guan, W. J. Martin, T. P. McDonald, M. K. Clements, Q. Jiang, Z. Zeng, M. Jacobson, D. L. Williams Jr., H. Yu, et al. Identification and Characterization of Novel Mammalian Neuropeptide FF-like Peptides That Attenuate Morphine-induced Antinociception J. Biol. Chem., September 28, 2001; 276(40): 36961 - 36969. [Abstract] [Full Text] [PDF] |
||||